Enterprise Value
940.9M
Cash
443.1M
Avg Qtr Burn
-24.03M
Short % of Float
16.13%
Insider Ownership
2.01%
Institutional Own.
79.47%
Qtr Updated
05/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NX-1607 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
NX-2127 (BTK degrader) Details Chronic lymphocytic leukemia, Blood cancer, Cancer, B-cell malignancies, Non-Hodgkin lymphoma, Diffuse large B cell lymphoma, Mantle cell lymphoma | Phase 1 Update | |
NX-5948 Details Cancer, B-cell malignancies | Phase 1 Update | |
NX-1607 + paclitaxel Details Solid tumor/s, Cancer | Phase 1a Data readout | |
DeTIL-0255 Details Ovarian cancer, Cancer, Cervical cancer, Endometrial cancer | Failed Discontinued |